Citations

Clear

1011 citation(s) found for "Barry, WT".

Patterns and predictors of BRCA 1/2 testing in young breast cancer survivors.
Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Barry, William T., Sprunck, Kim, Ligibel, Jennifer A. , Domchek, Susan M. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1514-1514

10.1200/jco.2016.34.15_suppl.1514 Get It

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
Barry, William T., Wenham, Robert M. , Hendrickson, Andrea E. Wahner , Armstrong, Deborah K. , Chan, Nancy , Lee, Jung‐Min , Penson, Richard T. , Cristea, Mihaela , Abbruzzese, James L. , Matsuo, Koji , Olawaiye, Alexander , Farooq, Sarah , Kohn, Elise C. , Matulonis, Ursula A. , Liu, Joyce F. , Cohn, David E. , Swisher, Elizabeth M. , Van Allen, Eliezer M , Shapiro, Geoffrey I. , Ivy, S. Percy

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5519-5519

10.1200/jco.2018.36.15_suppl.5519 Get It

Effects of clotrimazole troches on tacrolimus dosing in heart transplant recipients
Laub, Melissa R. , Crow, Stacy A., Personett, Heather A. , Dierkhising, Ross , Boilson, Barry A. , Boilson, Barry, Razonable, Raymund, Razonable, Raymund R.

Mayo Clinic

Transplant Infectious Disease | August 18, 2018 | Volume: 20 | Issue: 6 | Pages: No page available

10.1111/tid.12979 | PMID 30120865 Get It

AbstractBackgroundTacrolimus is a cornerstone of immunosuppression after transplantation but is highly susceptible to changes from interacting variables and has a narrow therapeutic index. Clotrimazole troches are commonly used as a non‐systemic antifungal to prevent oral candidiasis. Studies suggest that clotrimazole troches, though minimally absorbed systemically, may affect tacrolimus concentrations by inhibition of metabolic enzyme activity in the intestines. However, the magnitude of the impact of clotrimazole on tacrolimus dosing requirements to maintain goal levels is not well described.MethodsTo assess this, tacrolimus dose adjustments and trough concentrations were retrospectively examined in 95 heart transplant recipients before and after the discontinuation of clotrimazole.ResultsThe median percent tacrolimus dose change was an increase of 66.7% (IQR28.6%, 100%) after clotrimazole discontinuation, and the median trough concentration percent change from baseline to the first trough after clotrimazole discontinuation (in the absence of a dose change) was −42.5% (IQR−52.3%, −30.9%). Five cases of allograft rejection were observed.ConclusionIn conclusion, clotrimazole troches exert a meaningful interaction with tacrolimus that requires close monitoring and dose adjustment. The data from this single‐center study provide novel information that could guide providers on the degree of tacrolimus dose adjustment needed when discontinuing clotrimazole prophylaxis after heart transplantation.
Liraglutide and Weight Loss Among Patients with Advanced Heart Failure and a Reduced Ejection Fraction: Insights from the FIGHT Trial
Sharma, Abhinav , Ambrosy, Andrew P. , McNulty, Steven E., Mentz, Robert J. , Cooper, Lauren B. , Lala, Anuradha , Groake, John D., Borlaug, Barry A. , Borlaug, Barry A , Mentz, Robert J , DeVore, Adam D. , Margulies, Kenneth B. , Hernandez, Adrian F. , Felker, G. Michael , Vader, Justin M. , Velazquez, Eric J.

Mayo Clinic

ESC Heart Failure | August 18, 2018 | Volume: 5 | Issue: 6 | Pages: 1035-1043

10.1002/ehf2.12334 | PMID 30120812 Get It

Abstract Aims Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with HF and reduced ejection fraction (HFrEF) and a recent acute HF hospitalization remains unknown. Methods and results The Functional Impact of GLP-1 for Heart Failure Treatment study randomized 300 patients with HFrEF (ejection fraction ≤ 40%), both with and without diabetes and a recent HF hospitalization to liraglutide or placebo. The primary outcome for this post hoc analysis was the change in weight from baseline to last study visit. We conducted an ‘on-treatment’ analysis of patients with at least one follow-up visit on study drug (123 on liraglutide and 124 on placebo). The median age was 61 years, 21% were female, and 69% of patients had New York Heart Association functional Class III or IV symptoms. The median ejection fraction was 25% (25th, 75th percentile 19–32%). Liraglutide use was associated with a significant weight reduction [liraglutide −1.00 lbs vs. placebo 2.00 lbs; treatment difference −4.10 lbs; 95% confidence interval (CI) −7.94, −0.25; P = 0.0367; percentage treatment difference −2.07%, 95% CI −3.86, −0.28; P = 0.0237]. Similar results were seen after multivariable adjustments. Liraglutide also significantly reduced triglyceride levels (liraglutide 7.5 mg/dL vs. placebo 12.0 mg/dL; treatment difference −33.1 mg/dL; 95% CI −60.7, −5.6; P = 0.019). Conclusions Liraglutide is an efficacious weight loss agent in patients with HFrEF. These findings will require further exploration in a well-powered cardiovascular outcomes trial.
Timing of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor Initiation and Allograft Vasculopathy Progression and Outcomes in Heart Transplant Recipients
Briasoulis, Αlexandros , Pereira, Naveen L. , Boilson, Barry A. , Edwards, Brooks S., Adigun, Rosalyn , Maltais, Simon, Daly, Richard C. , Kushwaha, Sudhir S. , Asleh, Rabea , Briasoulis, Alexandros , Lerman, Amir

Mayo Clinic

ESC Heart Failure | July 18, 2018 | Volume: 5 | Issue: 6 | Pages: 1118-1129

10.1002/ehf2.12329 | PMID 30019530 Get It

Abstract Aims Early studies from the 1990s have shown that statins improve survival and attenuate cardiac allograft vasculopathy (CAV). However, little contemporary data are available on the incremental benefit of statins with the current use of new-generation immunosuppressive agents and the use of coronary intravascular ultrasound for assessment of CAV. We sought to investigate the effect of early statin (ES) as compared with late statin (LS) initiation after heart transplantation (HT) on long-term CAV progression and clinical outcomes in a large contemporary HT cohort. Methods and results We analysed a cohort of 409 adult HT recipients. CAV progression was assessed by serial coronary intravascular ultrasound volumetric measurements of the differences between baseline and last follow-up plaque volume (PV) and plaque index (PV/vessel volume ratio). CAV progression and clinical outcomes were compared between the ES (<2 years after HT) and the LS (>2 years after HT) groups. During a median follow-up of 8.2 years, ES resulted in significantly lower change (Δ) of plaque index (+3.8% ± 1.7% vs. +8.2% ± 3.6%; P = 0.0008) and PV (+0.8 ± 0.3 vs. +1.9 ± 1.2; P = 0.045) compared with LS group. In a Cox proportional hazards regression model and after adjustment for baseline characteristics, ES was associated with a 52% decreased risk of CAV-associated events (hazard ratio 0.48, 95% confidence interval: 0.27–0.91; P = 0.025) and a 42% decreased risk of the composite endpoint of all-cause mortality and CAV-associated events (hazard ratio 0.58, 95% confidence interval: 0.38–0.91; P = 0.019). Conclusions Early initiation of statin therapy after HT results in attenuated CAV progression as well as in decreased CAV-related events and mortality.
Exome Chip Analysis Identifies Low-Frequency and Rare Variants in MRPL38 for White Matter Hyperintensities on Brain Magnetic Resonance Imaging
Jian, Xueqiu , Satizábal, Claudia L. , Smith, Albert V. , Wittfeld, Katharina , Bis, Joshua C. , Smith, Jennifer A. , Hofer, Edith , Mishra, Aniket , Adams, Hieab H.H. , Li, Shuo , Teumer, Alexander , Zhao, Wei , Saba, Yasaman , Yanek, Lisa R. , Chauhan, Ganesh , Buchem, Mark A. van , Royle, Natalie A., Niessen, Wiro J. , Windham, B. Gwen , DeStefano, Anita L. , Habes, Mohamad , Heckbert, Susan R. , Palmer, Nicholette D., Lewis, Cora E. , Eiríksdóttir, Guðný , Maillard, Pauline , Mathias, Rasika A. , Divers, Jasmin, Beiser, Alexa S., Langner, Sönke , Rice, Kenneth , Bastin, Mark E. , Starr, John M. , Sidney, Stephen , Risacher, Shannon L. , Uitterlinden, André G. , Guðnason, Vilmundur , Rotter, Jerome I. , Schreiner, Pamela J. , Boerwinkle, Eric , Duijn, Cornelia M. van , Sarnowski, Bettina von , Gottesman, Rebecca F., Levy, Daniel , Sigurðsson, Sigurður , Vernooij, Meike W. , Schmidt, Reinhold, Wardlaw, Joanna M. , Mosley, Thomas H. , DeCarli, Charles , Bowden, Donald W. , Becker, Diane M. , Deary, Ian J. , Schmidt, Helena , Kardia, Sharon L. R., Debette, Stéphanie , Longstreth, W.T. , Seshadri, Sudha , Launer, Lenore J. , Fornage, Myriam , Group, for the neuroCHARGE Working, Dichgans, Martin , Rice, Kenneth , Palmer, Nicholette D. , DeCarli, Charles , Turner, Stephen T. , Dichgans, Martin , Wardlaw, Joanna Marguerite , Smith, Jennifer A , Adams, Hieab H H , Satizabal, Claudia L , Seshadri, Sudha , Bastin, Mark E , Teumer, Alexander , van Duijn, Cornelia M , Debette, Stephanie , Smith, Albert V , Palmer, Nicholette D , Rotter, Jerome I , Mathias, Rasika A , Rice, Ken , Levy, Daniel , Hsu, Fang‐Chi , Nho, Kwangsik T. , Hagenaars, Saskia P. , Nyquist, Paul , Freedman, Barry I. , Cushman, Mary , Bryan, Robert Nick , Homuth, Georg , Hernández, Maria del Carmen Valdés , Divers, Jasmin , Yang, Qiong , Maldjian, Joseph A. , Nauck, Matthias A. , Mazoyer, Bernard , Psaty, Bruce M. , Saykin, Andrew J. , Ikram, M. Arfan , Grabe, Hans Jörgen , Group, for the neuroCHARGE Working, Maillard, Pauline

Mayo Clinic

Stroke | July 12, 2018 | Volume: 49 | Issue: 8 | Pages: 1812-1819

10.1161/strokeaha.118.020689 | PMID 30002152 Get It

Background and Purpose— White matter hyperintensities (WMH) on brain magnetic resonance imaging are typical signs of cerebral small vessel disease and may indicate various preclinical, age-related neurological disorders, such as stroke. Though WMH are highly heritable, known common variants explain a small proportion of the WMH variance. The contribution of low-frequency/rare coding variants to WMH burden has not been explored. Methods— In the discovery sample we recruited 20 719 stroke/dementia-free adults from 13 population-based cohort studies within the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium, among which 17 790 were of European ancestry and 2929 of African ancestry. We genotyped these participants at ≈250 000 mostly exonic variants with Illumina HumanExome BeadChip arrays. We performed ethnicity-specific linear regression on rank-normalized WMH in each study separately, which were then combined in meta-analyses to test for association with single variants and genes aggregating the effects of putatively functional low-frequency/rare variants. We then sought replication of the top findings in 1192 adults (European ancestry) with whole exome/genome sequencing data from 2 independent studies. Results— At 17q25, we confirmed the association of multiple common variants in TRIM65 , FBF1 , and ACOX1 ( P <6×10 −7 ). We also identified a novel association with 2 low-frequency nonsynonymous variants in MRPL38 (lead, rs34136221; P EA =4.5×10 −8 ) partially independent of known common signal ( P EA(conditional) =1.4×10 −3 ). We further identified a locus at 2q33 containing common variants in NBEAL1 , CARF , and WDR12 (lead, rs2351524; P all =1.9×10 −10 ). Although our novel findings were not replicated because of limited power and possible differences in study design, meta-analysis of the discovery and replication samples yielded stronger association for the 2 low-frequency MRPL38 variants ( P rs34136221 =2.8×10 −8 ). Conclusions— Both common and low-frequency/rare functional variants influence WMH. Larger replication and experimental follow-up are essential to confirm our findings and uncover the biological causal mechanisms of age-related WMH.
A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus
Anguiano-Zarate, Stephanie S., Matchett, William E. , Marzi, Andrea , Barry, Michael A. , Barry, Michael A , Nehete, Pramod N. , Sastry, K. Jagannadha

Mayo Clinic

The Journal of Infectious Diseases | June 29, 2018 | Volume: 218 | Issue: 12 | Pages: 1883-1889

10.1093/infdis/jiy411 | PMID 29982595 Get It

The Strengths and Limitations of E/E' in Heart Failure with Preserved Ejection Fraction
Obokata, Masaru , Borlaug, Barry A. , Borlaug, Barry A , Obokata, Masaru

Mayo Clinic

European Journal of Heart Failure | June 22, 2018 | Volume: 20 | Issue: 9 | Pages: 1312-1314

10.1002/ejhf.1250 | PMID 29932475 Get It

What Do You Want From Your Echocardiogram?
Reddy, Yogesh N.V. , Borlaug, Barry A. , Nishimura, Rick , Borlaug, Barry A

Mayo Clinic

Journal of the American Heart Association | June 1, 2018 | Volume: 7 | Issue: 11 | Pages: No page available

10.1161/jaha.118.009462 | PMID 29858373 Get It